Molecular mechanisms of antithrombin deficiency in two Chinese families

Summary

We investigated the molecular mechanisms responsible for type I congenital antithrombin (AT) deficiency in two unrelated Chinese pedigrees manifesting multiple site venous thrombosis. Phenotype analysis showed both probands had almost 50% of normal AT levels. Direct sequencing of amplified DNA revealed 2757C>T in proband 1 and 13328G>A in proband 2, predicting a heterozygous Thr98Ile (T98I) and Ala404Thr (A404T), respectively. No proband had 20210A allele or factorV Leiden mutation. Transient expression of complementary DNA coding for the mutations in COS-7 cells showed impaired secretion of the mutant molecules. Real-time quantitative PCR indicated that the mutant AT mRNA was transcribed at a similar or even higher level as that of wild-type (wt). Pulse-chase labeling studies suggested both AT variants did not accumulate, but degraded intracellularly. Immunohistochemical staining of the transfected cells revealed that CHO cells expressing the AT-I98 mutant were stained diffusely without perinuclear enhancement and cells expressing AT-T404 mutant mainly in the whole cytoplasm with weaker perinuclear enhancement. We conclude that the impaired secretion of the mutant AT molecules, due to intracellular degradation, is the molecular pathogenesis of AT deficiency caused by T98I and A404T mutation for the two families, respectively.

Keywords

Antithrombin deficiency - gene mutation - venous thrombosis

^* These authors contribute to the work equally and should be considered as co-first author.

• References

• 1 Lane DA, Bayston T, Olds RJ. et al Antithrombin mutation database: 2_nd (1997) update. Thromb Haemost 1997; 77: 197-211.
• 2 Olds RJ, Lane DA, Chowdhury V. et al Complete nucleotide sequence of the antithrombin gene: evidence for homologous recombination causing thrombophilia. Biochemistry 1993; 32: 4216-24.
• 3 Chandra T, Stackhouse R, Kidd VJ. et al Isolation and sequence characterization of a cDNA clone of human antithrombin III. Proc Natl Acad Sci USA 1983; 80: 1845-8.
• 4 Qihua F, Xinguo X, Qiulan D. et al Type I antithrombin deficiency due to 13389G deletion in antithrombin gene. Chin J Hematol 2002; 23: 588-90.
• 5 Wen-Bin W, Qi-Hua F, Qiu-Lan D. et al Characterization of molecular defect of 13387–9delG mutated antithrombin in inherited type I antithrombin deficiency. Blood Coagul Fibrinolysis 2005; 16: 149-55.
• 6 Colosimo A, Xu Z, Novelli G. et al Simple version of “megaprimer” PCR for site-directed mutagenesis. Biotechniques 1999; 26: 870-3.
• 7 Lane DA, Olds RJ, Conard J. et al Pleiotropic effects of antithrombin strand 1C substitution mutations. J Clin Invest 1992; 90: 2422-33.
• 8 Tokunaga F, Shirotani H, Hara K. et al Intracellular degradation of secretion defect-type mutants of antithrombin is inhibited by proteasomal inhibitors. FEBS Lett 1997; 412: 65-9.
• 9 Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965; 13: 516-30.
• 10 Shirotani H, Tokunaga F, Koide T. Cellular and functional characterization of three recombinant antithrombin mutants that caused pleiotropic effect-type deficiency. J Biochem 1999; 125: 253-62.
• 11 Nagaizumi K, Inaba H, Amano K. et al Five novel and four recurrent point mutations in the antithrombin gene causing venous thrombosis. Int J Hematol 2003; 78: 79-83.
• 12 Sheffield WP, Castillo JE, Blajchman MA. Intracellular events determine the fate of antithrombin Utah. Blood 1995; 86: 3461-7.
• 13 Skinner R, Abrahams JP, Whisstock JC. et al The 2.6 Å structure of antithrombin indicates a conformational change at the heparin binding site. J Mol Biol 1997; 266: 601-9.
• 14 Jin L, Abrahams JP, Skinner R. et al The anticoagulant activation of antithrombin by heparin. Proc Natl Acad Sci USA 1997; 94: 14683-8.
• 15 Mille B, Watton J, Barrowcliffe TW. et al Role of N- and C-terminal animo acids in antithrombin binding to pentasaccharide. J Biol Chem 1994; 269: 29435-43.
• 16 Verpy E, Couture-Tosi E, Eldering E. et al Crucial residues in the carboxy-terminal end of C1 inhibitor revealed by pathogenic mutants impaired in secretion or function. J Clin Invest 1995; 95: 350-9.